- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The Patents (Isle of Man) Order 2013, Paragraph 34.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
34. After section 128 insert―U.K.
128A.—(1) In this Act [F2a “compulsory pharmaceutical licence”] means a compulsory licence granted under Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to countries with public health problems(1) (referred to in this Act as “the Compulsory Licensing Regulation”).
(2) In the application to [F3compulsory pharmaceutical] licences of the provisions of this Act listed in subsection (3)—
(a)references to a licence under a patent,
(b)references to a right under a patent, and
(c)references to a proprietary interest under a patent,
include [F4a compulsory pharmaceutical] licence.
(3) The provisions referred to in subsection (2) are—
sections 32 and 33 (registration of patents etc);
section 37 (determination of right to patent after grant);
section 38 (effect of transfer etc of patent under section 37), apart from subsection (2) and subsections (3) to (5) so far as relating to subsection (2);
section 41 (amount of compensation);
section 46(2) (notice of application for entry that licences are available as of right);
section 57(1) and (2) (rights of third parties in respect of Crown use).
(4) In the following provisions references to this Act include the Compulsory Licensing Regulation—
sections 97 to 99B, 101 to 103, 105 and 107 (legal proceedings);
section 119 (service by post);
section 120 (hours of business and excluded days);
section 121 (comptroller’s annual report);
section 123 (rules);
section 124A (use of electronic communications);
section 130(8) (disapplication of Part 1 of Arbitration Act 1996(2)).
(5) In section 108 (licences granted by order of comptroller) the reference to a licence under section 11, 38, 48 or 49 includes [F5a compulsory pharmaceutical] licence.
(6) References in this Act to the Compulsory Licensing Regulation are to that Regulation as amended from time to time.
128B.—(1) Schedule 4A contains provision about the application of this Act in relation to supplementary protection certificates and other provision about such certificates.
(2) In this Act a “supplementary protection certificate” means a certificate issued under—
(a)[F6“Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6th May 2009 concerning the supplementary protection certificate for medicinal products], or
(b)Regulation (EC) No 1610/96 of the European Parliament and of the Council of 23 July 1996 concerning the creation of a supplementary protection certificate for plant protection products(3).”.
Textual Amendments
F1Words in Sch. para. 34 substituted (31.12.2020) by The Patents (Isle of Man) (Amendment) (EU Exit) Order 2019 (S.I. 2019/1327), arts. 1, 2(3)(a); 2020 c. 1, Sch. 5 para. 1(1)
F2Words in Sch. para. 34 substituted (31.12.2020) by The Patents (Isle of Man) (Amendment) (EU Exit) Order 2019 (S.I. 2019/1327), arts. 1, 2(3)(b); 2020 c. 1, Sch. 5 para. 1(1)
F3Words in Sch. para. 34 substituted (31.12.2020) by The Patents (Isle of Man) (Amendment) (EU Exit) Order 2019 (S.I. 2019/1327), arts. 1, 2(3)(c)(i); 2020 c. 1, Sch. 5 para. 1(1)
F4Words in Sch. para. 34 substituted (31.12.2020) by The Patents (Isle of Man) (Amendment) (EU Exit) Order 2019 (S.I. 2019/1327), arts. 1, 2(3)(c)(ii); 2020 c. 1, Sch. 5 para. 1(1)
F5Words in Sch. para. 34 substituted (31.12.2020) by The Patents (Isle of Man) (Amendment) (EU Exit) Order 2019 (S.I. 2019/1327), arts. 1, 2(3)(d); 2020 c. 1, Sch. 5 para. 1(1)
F6Words in Sch. para. 34 substituted (1.6.2016) by The Patents (Isle of Man) (Amendment) Order 2016 (S.I. 2016/559), art. 1, Sch. para. 3
Commencement Information
I1Sch. para. 34 in force at 11.11.2013, see art. 1
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: